TrialThe journal of headache and pain2021

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.

Michael Ament et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.